Clinical Trials · NCT05316935
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
- Phase
- Phase 2/Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Xiaojun Chen
- Enrollment
- 80
- Start date
- Jul 2022
- Locations
- 2 sites, China
- Primary endpoint
- Complete response rates within 28 weeks of treatment